{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T22:53:14Z","timestamp":1771023194738,"version":"3.50.1"},"reference-count":40,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2018,2,7]],"date-time":"2018-02-07T00:00:00Z","timestamp":1517961600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Polish Ministry of Science and Higher Education","award":["N402 268836"],"award-info":[{"award-number":["N402 268836"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Psychopharmacology"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Augmentation of sarcosine, a natural inhibitor of the glycine transporter type I, normalizes glutamatergic neurotransmission, having beneficial impact on primary negative symptoms in schizophrenia and may also influence immune system and interleukin 6 (IL\u20106) levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>Finding a relationship between initial IL\u20106 serum concentrations or its changes and severity of symptoms as a result of sarcosine addition to stable antipsychotic treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>Fifity\u2010eight individuals with schizophrenia with predominantly negative symptoms completed a 6\u2010month randomized, double\u2010blind placebo\u2010controlled prospective study. Patients received 2\u00a0g of sarcosine (<jats:italic>n<\/jats:italic>\u00a0=\u00a029) or placebo (<jats:italic>n<\/jats:italic>\u00a0=\u00a030) daily per os. We measured IL\u20106 levels and severity of symptoms at the beginning, after 6\u00a0weeks and 6\u00a0months. As main clinical tools, we used Positive and Negative Syndrome Scale (PANSS) and Calgary depression scale for schizophrenia (CDSS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Augmentation with sarcosine had no effect on IL\u20106 serum levels in all time points. We noted significant improvements in negative symptoms, general psychopathology, and total PANSS score in the sarcosine group. We found correlation of initial serum IL\u20106 with severity of positive symptoms and negative association between IL\u20106 levels reduction and positive symptoms reduction.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Sarcosine does not significantly affect IL\u20106 concentrations but IL\u20106 may be involved in mechanisms related to the presence of positive symptoms.<\/jats:p><\/jats:sec>","DOI":"10.1002\/hup.2652","type":"journal-article","created":{"date-parts":[[2018,2,8]],"date-time":"2018-02-08T03:36:39Z","timestamp":1518060999000},"source":"Crossref","is-referenced-by-count":12,"title":["Serum levels of interleukin 6 in schizophrenic patients during treatment augmentation with sarcosine (results of the <scp>PULSAR<\/scp> study)"],"prefix":"10.1002","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8559-1078","authenticated-orcid":false,"given":"Dominik","family":"Strzelecki","sequence":"first","affiliation":[{"name":"Department of Affective and Psychotic Disorders Medical University of \u0141\u00f3d\u017a  \u0141\u00f3d\u017a Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7016-636X","authenticated-orcid":false,"given":"Ma\u0142gorzata","family":"Urban\u2010Kowalczyk","sequence":"additional","affiliation":[{"name":"Department of Affective and Psychotic Disorders Medical University of \u0141\u00f3d\u017a  \u0141\u00f3d\u017a Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6159-6579","authenticated-orcid":false,"given":"Adam","family":"Wysoki\u0144ski","sequence":"additional","affiliation":[{"name":"Department of Old Age Psychiatry and Psychotic Disorders Medical University of \u0141\u00f3d\u017a  \u0141\u00f3d\u017a Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,2,7]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0920-9964(90)90005-R"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2006.01858.x"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2016.05.010"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/bs.apha.2016.01.006"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0173(99)00050-8"},{"issue":"152","key":"e_1_2_7_7_1","article-title":"The value of interleukin 6 as a peripheral diagnostic marker in schizophrenia","volume":"16","author":"Chase K. A.","year":"2016","journal-title":"BMC Psychiatry"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.3109\/10673229609017192"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2016.05.020"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2012.110"},{"issue":"6","key":"e_1_2_7_11_1","first-page":"449","article-title":"Interleukin\u20106: The missing element of the neurocognitive deterioration in schizophrenia? The focus on genetic underpinnings, cognitive impairment and clinical manifestation","volume":"265","author":"Frydecka D.","year":"2015","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(98)00367-9"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0896-6273(03)00672-X"},{"issue":"66","key":"e_1_2_7_14_1","article-title":"A double\u2010blind randomized study assessing safety and efficacy following one\u2010year adjunctive treatment with bitopertin, a glycine reuptake inhibitor, in Japanese patients with schizophrenia","volume":"16","author":"Hirayasu Y.","year":"2016","journal-title":"BMC Psychiatry"},{"issue":"1","key":"e_1_2_7_15_1","first-page":"21","article-title":"Effects of olanzapine on plasma levels of catecholamine metabolites, cytokines, and brain\u2010derived neurotrophic factor in schizophrenic patients","volume":"22","author":"Hori H.","year":"2007","journal-title":"International Clinical Psychopharmacology"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040622315579059"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.12740\/PP\/25520"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(99)00171-1"},{"issue":"1","key":"e_1_2_7_19_1","first-page":"S153","article-title":"Increased interleukin\u20106 and tumor necrosis factor alpha in first episode schizophrenia patients versus healthy controls","volume":"24","author":"Kubistova A.","year":"2012","journal-title":"Psychiatria Danubina"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(94)00049-W"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20117"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-005-2199-1"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2011.04.013"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3956(99)00029-1"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.156.1.145"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2007.09.024"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/jne.12033"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbm030"},{"issue":"2","key":"e_1_2_7_29_1","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1503\/jpn.140126","article-title":"Increased levels of IL\u20106 in the cerebrospinal fluid of patients with chronic schizophrenia\u2010\u2010significance for activation of the kynurenine pathway","volume":"40","author":"Schwieler L.","year":"2015","journal-title":"Journal of Psychiatry & Neuroscience"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.13741"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12396"},{"issue":"4","key":"e_1_2_7_32_1","first-page":"L471","article-title":"Cigarette smoking decreases bioactive interleukin\u20106 secretion by alveolar macrophages","volume":"263","author":"Soliman D. M.","year":"1992","journal-title":"The American Journal of Physiology"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.3109\/15622975.2011.583941"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.3390\/nu7105427"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S75734"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neures.2016.11.002"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200620110-00001"},{"issue":"2","key":"e_1_2_7_38_1","first-page":"247","article-title":"Schizophrenia and infections: The eyes have it","volume":"43","author":"Torrey E. F.","year":"2017","journal-title":"Schizophrenia Bulletin"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2014.03.005"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-010-5788-9"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.8.856"}],"container-title":["Human Psychopharmacology: Clinical and Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhup.2652","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hup.2652","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T08:47:00Z","timestamp":1695545220000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hup.2652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,7]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1002\/hup.2652"],"URL":"https:\/\/doi.org\/10.1002\/hup.2652","archive":["Portico"],"relation":{},"ISSN":["0885-6222","1099-1077"],"issn-type":[{"value":"0885-6222","type":"print"},{"value":"1099-1077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,7]]},"article-number":"e2652"}}